Display options
Cite
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012;2(2):35-49doi: 10.3390/jpm2020035.
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012). Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. Journal of personalized medicine, 2(2), 35-49. https://doi.org/10.3390/jpm2020035
Kelleher, Fergal C, et al. "Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer." Journal of personalized medicine vol. 2,2 (2012): 35-49. doi: https://doi.org/10.3390/jpm2020035
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035. PMID: 25562798; PMCID: PMC4251364.
Copy Download .nbib Format: NLM
Share it on

J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035.

Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.

Journal of personalized medicine

Fergal C Kelleher, Benjamin Solomon, Grant A McArthur

Affiliations

  1. Divisions of Cancer Medicine/Cancer Research, Peter MacCallum Cancer Centre, Locked Bag 1A'Beckett St Victoria 8006, Australia. [email protected].
  2. Divisions of Cancer Medicine/Cancer Research, Peter MacCallum Cancer Centre, Locked Bag 1A'Beckett St Victoria 8006, Australia. [email protected].
  3. Divisions of Cancer Medicine/Cancer Research, Peter MacCallum Cancer Centre, Locked Bag 1A'Beckett St Victoria 8006, Australia. [email protected].

PMID: 25562798 PMCID: PMC4251364 DOI: 10.3390/jpm2020035

Abstract

The incorporation of individualized molecular therapeutics into routine clinical practice for both non-small cell lung cancer (NSCLC) and melanoma are amongst the most significant advances of the last decades in medical oncology. In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. More recently the EML4-ALK fusion gene which occurs in 3-5% of NSCLC has been found to predict sensitivity to crizotinib an inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. Similarly in melanoma, 50% of cases have BRAF mutations in exon 15 mostly V600E and these cases are sensitive to the BRAF inhibitors vemurafenib or dabrafenib. In a Phase III study of advanced melanoma cases with this mutation vemurafenib improved survival from 64% to 84% at 6 months, when compared with dacarbazine. In both NSCLC and melanoma clinical benefit is not obtained in patients without these genomic changes, and moreover in the case of vemurafenib the therapy may theoretically induce proliferation of cases of melanoma without BRAF mutations. An emerging clinical challenge is that of acquired resistance after initial responses to targeted therapeutics. Resistance to the TKI's in NSCLC is most frequently due to acquisition of secondary mutations within the tyrosine kinase of the EGFR or alternatively activation of alternative tyrosine kinases such as C-MET. Mechanisms of drug resistance in melanoma to vemurafenib do not involve mutations in BRAF itself but are associated with a variety of molecular changes including RAF1 or COT gene over expression, activating mutations in RAS or increased activation of the receptor tyrosine kinase PDGFRβ. Importantly these data support introducing re-biopsy of tumors at progression to continue to personalize the choice of therapy throughout the patient's disease course.

References

  1. N Engl J Med. 2009 Sep 3;361(10):958-67 - PubMed
  2. Cancer Discov. 2011 Jun;1(1):78-89 - PubMed
  3. Cancer Cell. 2010 Jan 19;17(1):77-88 - PubMed
  4. Cancer Res. 2008 Sep 1;68(17):6913-21 - PubMed
  5. Cell. 2007 Dec 14;131(6):1190-203 - PubMed
  6. Nat Genet. 2004 Sep;36(9):961-8 - PubMed
  7. Clin Cancer Res. 2011 Mar 1;17(5):1169-80 - PubMed
  8. N Engl J Med. 2010 Jun 24;362(25):2380-8 - PubMed
  9. Nature. 2010 Dec 16;468(7326):968-72 - PubMed
  10. Lancet Oncol. 2011 Sep;12 (9):913-22 - PubMed
  11. J Clin Oncol. 2003 Jun 15;21(12):2237-46 - PubMed
  12. N Engl J Med. 2012 Jan 19;366(3):207-15 - PubMed
  13. JAMA. 2003 Oct 22;290(16):2149-58 - PubMed
  14. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  15. N Engl J Med. 2005 Nov 17;353(20):2135-47 - PubMed
  16. N Engl J Med. 2010 Dec 2;363(23 ):2191-9 - PubMed
  17. Int J Cancer. 2006 Dec 1;119(11):2586-91 - PubMed
  18. Cancer Res. 2011 Sep 15;71(18):6051-60 - PubMed
  19. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  20. N Engl J Med. 2010 Oct 28;363(18):1734-9 - PubMed
  21. PLoS One. 2011;6(6):e20351 - PubMed
  22. J Clin Oncol. 2006 Sep 10;24(26):4340-6 - PubMed
  23. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22 - PubMed
  24. Clin Cancer Res. 2008 Sep 15;14 (18):5731-4 - PubMed
  25. Cancer Res. 2005 Mar 1;65(5):1642-6 - PubMed
  26. N Engl J Med. 2010 Aug 26;363(9):809-19 - PubMed
  27. Nature. 2010 Mar 18;464(7287):427-30 - PubMed
  28. N Engl J Med. 2005 Feb 24;352(8):786-92 - PubMed
  29. Nature. 2010 Mar 18;464(7287):431-5 - PubMed
  30. J Clin Oncol. 2011 May 20;29(15):2046-51 - PubMed
  31. Science. 2004 Jun 4;304(5676):1497-500 - PubMed
  32. Sci Transl Med. 2010 Dec 15;2(62):62ra93 - PubMed
  33. Nature. 2009 Jan 29;457(7229):599-602 - PubMed
  34. Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 - PubMed
  35. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 - PubMed
  36. J Thorac Oncol. 2011 Apr;6(4):774-80 - PubMed
  37. N Engl J Med. 2004 May 20;350(21):2129-39 - PubMed
  38. Lancet Oncol. 2010 Feb;11(2):121-8 - PubMed
  39. Int J Cancer. 2005 Nov 1;117(2):294-9 - PubMed
  40. Nature. 2008 Oct 23;455(7216):1069-75 - PubMed
  41. PLoS Med. 2005 Mar;2(3):e73 - PubMed
  42. Science. 2007 May 18;316(5827):1039-43 - PubMed
  43. J Clin Oncol. 2011 Jul 20;29(21):2904-9 - PubMed
  44. N Engl J Med. 2010 Oct 28;363(18):1693-703 - PubMed
  45. Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 - PubMed
  46. Lancet Oncol. 2011 Aug;12(8):735-42 - PubMed
  47. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40 - PubMed
  48. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  49. N Engl J Med. 2005 Jul 14;353(2):123-32 - PubMed
  50. J Clin Oncol. 2010 Oct 20;28(30):4616-20 - PubMed
  51. Nature. 2007 Dec 6;450(7171):893-8 - PubMed
  52. Sci Transl Med. 2011 Mar 23;3(75):75ra26 - PubMed
  53. Clin Cancer Res. 2011 Apr 15;17(8):2081-6 - PubMed
  54. J Clin Oncol. 2009 Sep 10;27(26):4232-5 - PubMed
  55. N Engl J Med. 2009 Sep 3;361(10):947-57 - PubMed
  56. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 - PubMed
  57. Nature. 2004 Sep 30;431(7008):525-6 - PubMed
  58. Cell. 2010 Jan 22;140(2):209-21 - PubMed
  59. Nature. 2007 Aug 2;448(7153):561-6 - PubMed
  60. J Clin Oncol. 2011 May 20;29(15):2121-7 - PubMed
  61. J Clin Oncol. 2012 Jan 20;30(3):316-21 - PubMed
  62. Nature. 2010 Dec 16;468(7326):973-7 - PubMed

Publication Types